Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 540975 | NSE Symbol : ASTERDM | ISIN : INE914M01019 | Industry : Healthcare |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
27-Jan-2025	31-Jan-2025	Quarterly Results	Aster DM Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2025 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI Listing Regulations we hereby inform you that a meeting of the Board of Directors of Aster DM Healthcare Limited (Company) is scheduled to be held on Friday January 31 2025 inter alia to: 1. Consider and approve the unaudited financial results (both standalone and consolidated) of the Company for the quarter ended December 31 2024 2. Consider declaration of interim dividend for the financial year 2024-25. We request you to kindly take the above information on record. Outcome of Board Meeting - Financial Results, Interim Dividend Results - Financial Results for the Quarter ended December 31, 2024 Board approves Interim Dividend (As per BSE Announcement Dated on 31/01/2025)
26-Nov-2024	29-Nov-2024	Preferential Issue	Aster DM Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/11/2024 inter alia to consider and approve 1. To evaluate and approve the proposal for issuance of equity shares by way of preferential allotment of up to 5% paid-up capital of the Company (on post issue basis) in accordance with the applicable laws subject to such regulatory/statutory approvals as may be required and the approval of shareholders of the Company. 2.To consider conducting the postal ballot to seek the approval of shareholders inter alia in respect of aforesaid proposal if the same is approved by the Board. 3.ln compliance with SEBI (PIT) Regulations 2015 the Trading Window for dealing in securities of the Company shall be closed for all Designated Persons from the intimation of this notice up to 48 hours from the time of disclosure of outcome of the above meeting to the Stock Exchanges. 4.Regulation 30 of Securities and Exchange Board of India (LODR) Regulation 2015 we wish to inform you that an investors conference call is scheduled on Nov 29 2024. The Board of Directors at their meeting held on 29th November 2024 have, inter alia, approved a preferential allotment for consideration other than cash, shifting of registered office, amalgamation, postal ballot notice and entered into a merger framework agreement ('MFA'), Shareholders' Agreement (SHA) and certain other agreements in relation to foregoing matters. Kindly take the above said information on record. The Board of Directors at their meeting held on 29.11.2024, approved the shifting of registered office of the Company from the state of Karnataka to the state of Telangana subject to approval of the shareholders of the Company and approval of Regional Director. Kindly take the above said information on record. (As Per BSE Announcement Dated on 29.11.2024)
17-Oct-2024	23-Oct-2024	Quarterly Results	Aster DM Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2024 inter alia to consider and approve the Unaudited Financial Results (both standalone and consolidated) of the Company for the quarter and half year ended September 30 2024. Please find the unaudited financial results (Standalone and consolidated) for the quarter and half year ended September 30, 2024 along with the Limited review report. Please find the financial results for quarter and half year ended September 30,2024 along with limited review report Please find enclosed the unaudited financial results for the quarter and half year ended September 30,2024 (As per BSE Announcement Dated on 23/10/2024)
25-Jul-2024	31-Jul-2024	Quarterly Results	Aster DM Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2024 inter alia to consider and approve the unaudited financial results (both standalone and consolidated) of the Company for the quarter ended June 30 2024. We request you to kindly take the same on record. The Board of Directors at their meeting held on July 31, 2024 have, inter alia, approved the unaudited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2024. Kindly take the above said information on record as per the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Read less.. (As Per BSE Announcement Dated on 31.07.2024)
22-May-2024	28-May-2024	Final Dividend	Aster DM Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 inter alia to consider and approve 1. The Audited Financial Results (both standalone and consolidated) of the Company for the quarter and year ended March 31 2024. 2. To recommend final dividend if any on the equity shares of the Company for the financial year ended March 31 2024 subject to approval of the shareholders at the ensuing Annual General Meeting of the Company. We request you to kindly take the same on record. Please be informed that the Board of Directors of the Company at their meeting held on 28th May, 2024 has approved the recommendation of the final dividend for the Financial Year ended 31st March, 2024, subject to the approval of the Shareholders at the ensuing Annual General meeting. We request you to kindly take the above said information on record Please be informed that the Board of Directors at their meeting held on 28th May, 2024 have inter alia approved the audited financial results (standalone and consolidated) for the 4th quarter and year ended 31st March, 2024. Kindly take the above said information on record With reference to the above captioned Subject, Please be informed that the Board of Directors at their meeting held on May 28, 2024 have approved the reappointment of Ms. Alisha Moopen (DIN: 02432525) as the Deputy Managing Director of the Company for a term of 5 years with effect from August 07, 2024 subject to the approval of the shareholders. We request you to kindly take the above said information on record. (As Per BSE Announcement dated on 28.05.2024)
05-Apr-2024	12-Apr-2024	Special Dividend	Aster DM Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/04/2024 inter alia to consider and approve 1. Declaration of interim dividend for the financial year 2023-24. 2. Declaration of special dividend on account of the segregation of the GCC business through the sale by Affinity Holdings Pvt Ltd a wholly owned material subsidiary of the Company of entities conducting business in the GCC region to Alpha GCC Holdings Limited. Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, the Board of Directors approved declaration of a special dividend of INR 118 /- per share payable to those shareholders whose names stand on the Register of Members of the Company as on the Record Date. The Special dividend will be paid within 30 (thirty) days from the date of the declaration. The Board has decided not to declare an interim dividend for the financial year 2023-24. The Board may consider declaration of final dividend for the financial year 2023-24 at the Board meeting considering the approval of audited financial statements for FY 2023-24. Kindly take the above said information on record as per the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 the Board of Directors approved the declaration of Special Dividend of INR 118 /- per share payable to those shareholders whose name stand on the Register of Members of the Company as on the record date 23rd April, 2024. Request you to kindly take the above said information on record. (As Per BSE Announcement Dated on 12.04.2024)
02-Feb-2024	08-Feb-2024	Quarterly Results	Aster DM Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 inter alia to consider and approve With reference to captioned subject we wish to inform you that meeting of the Board of Directors of the Company will be held on Thursday February 08 2024 inter-alia to consider and approve the unaudited financial results (both standalone and consolidated) of the Company for the quarter ended December 31 2023. With reference to the captioned subject, we wish to inform you that: 1. The Meeting of the Board of Directors commenced at 02:30 pm (IST) and concluded at 6:55pm (IST). 2. The unaudited financial results (standalone and consolidated) of the Company for the quarter ended December 31, 2023 together with the Limited Review Report has been reviewed by the Audit Committee and considered and approved by the Board of Directors, has been enclosed herewith as Annexure-1. (As Per BSE Announcement dated on 08.02.2024)
15-Jan-2024	15-Jan-2024	Others	The board of directors of the Company ('Board') held a meeting on January 15, 2024 to discuss progress of the transaction between Affinity Holdings Private Limited ('Affinity') and Alpha GCC Holdings Limited ('Buyer') for segregation of the Company''s GCC business. The Board was briefed that there has been satisfactory progress on conditions precedent for the transaction and Affinity and the Buyer are aiming to complete the transaction soon. The Board also discussed the proposed utilization of the transaction proceeds receivable at closing of the transaction. Following deliberations regarding future expansion plans, capex requirements, cash reserves, the Board is desirous to consider distribution of 70% to 80% of the upfront consideration of USD 903 million, as dividend to its shareholders. i.e in the range of INR 110/- to INR 120/- per share. The details are provided in attached letter and Annexure-1. Kindly take the above said information on record.
28-Nov-2023	28-Nov-2023	Others	In relation to the captioned subject we hereby inform you that, the Board of Directors of the Company has its meeting held on November 28, 2023 approved agreements setting forth non-compete and other obligations of the Company and Affinity in respect of the Transaction. The details required as per SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 pertaining to continuous disclosure requirements for listed entities under Regulation 30 and 30A of the SEBI Listing Regulations, has been enclosed in Annexure-II.
07-Nov-2023	14-Nov-2023	Quarterly Results	Aster DM Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2023 inter alia to consider and approve With reference to captioned subject we wish to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday November 14 2023 inter-alia to consider and approve the unaudited financial results (both standalone and consolidated) of the Company for the quarter and half year ended September 30 2023. With reference to the captioned subject please find enclosed the unaudited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30, 2023 together with the Limited Review Report reviewed by the Audit Committee and considered and approved by the Board of Directors. Publication of the results in the Newspaper is being done as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly take the above said information on record as per the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (As Per BSE Announcement Dated on 15.11.2023)
07-Aug-2023	14-Aug-2023	Quarterly Results	Aster DM Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 inter alia to consider and approve With reference to captioned subject we wish to inform you that meeting of the Board of Directors of the Company will be held on Monday August 14 2023 inter-alia to consider and approve the unaudited financial results (both standalone and consolidated) of the Company for the quarter ended June 30 2023. With reference to the captioned subject, we wish to inform you that: 1. The Meeting of the Board of Directors commenced at 01:00 pm (IST) and concluded at 05:00 pm (IST). 2. The unaudited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2023 together with the Limited Review Report has been reviewed by the Audit Committee and considered and approved by the Board of Directors, has been enclosed herewith as Annexure-1. 3. Publication of the results in the Newspaper is being done as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The unaudited financial results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2023, together with Limited Review Report has been reviewed by the Audit Committee and considered and approved by the Board of Directors. (As Per BSE Announcement Dated on 14.08.2023)
19-May-2023	25-May-2023	Accounts	Aster DM Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2023 inter alia to consider and approve With reference to captioned subject we wish to inform you that meeting of the Board of Directors of the Company will be held on Thursday May 25 2023 inter-alia to consider and approve the Audited Financial Results (both standalone and consolidated) of the Company for the quarter and year ended March 31 2023. With reference to the captioned subject, we wish to inform you that, upon recommendation of the Nomination and Remuneration Committee and Audit Committee, the Board of Directors of the Company at their meeting held on May 25, 2023 have approved the appointment of Mr. Amitabh Johri and Mr. Sunil Kumar M R as Joint Chief Financial Officers and Key Managerial Personnel of the Company with effect from May 25, 2023 In compliance with Circular Number CIR/CFD/CMD/4/2015 dated September 09, 2015 pertaining to continuous disclosure requirements for Listed Entities under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Annexure I for your records. (As Per BSE Announcement Dated on 25.05.2023)
17-Mar-2023	16-Mar-2023	Change in Other Executives	With reference to the captioned subject, we wish to inform you that, upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company on March 16, 2023 has approved the appointment of Dr. Nitish Shetty as the Chief Executive Officer (CEO) of Aster DM Healthcare Ltd - India (not in the capacity of KMP) effect from March 16, 2023. Dr. Nitish Shetty who has been in leadership positions across various healthcare organizations joined Aster as CEO of Aster CMI Hospital, Bengaluru in 2014 . He was later promoted as the Regional Director, Aster Hospitals (Karnataka and Maharashtra cluster) & Aster Labs. Based on the recommendations of the NRC and the Board of Directors he is now being elevated to the role of CEO of Aster DM Healthcare Ltd - India. Dr. Nitish Shetty is a strong healthcare services professional with an M.D in Hospital Administration from KMC Manipal and MBBS from M.R Medical College. His profile is enclosed as Annexure - I.
08-Feb-2023	14-Feb-2023	Quarterly Results	Aster DM Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve With reference to captioned subject we wish to inform you that meeting of the Board of Directors of the Company will be held on Tuesday February 14 2023 inter-alia to consider and approve the unaudited financial results (both standalone and consolidated) of the Company for the quarter ended December 31 2022. 1. Outcome of Board Meeting held on February 14, 2023, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') 2. Unaudited financial results for the quarter ended December 31, 2022 pursuant to Regulation 33 of the Listing Regulations With reference to the captioned subject, we wish to inform you that: 1. The Meeting of the Board of Directors Board commenced at 2.30 p.m. (IST) and concluded at 8:50 p.m. (IST). 2. The unaudited financial results (standalone and consolidated) of the Company for the quarter ended December 31, 2022 together with the Limited Review Report as reviewed by the Audit Committee and considered and approved by the Board of Directors, has been enclosed herewith as Annexure-1. (As Per BSE Announcement Dated on 14.02.2023)
03-Nov-2022	10-Nov-2022	Quarterly Results	Aster DM Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2022 inter alia to consider and approve With reference to captioned subject we wish to inform you that meeting of the Board of Directors of the Company will be held on Thursday November 10 2022 inter-alia to consider and approve the unaudited financial results (both standalone and consolidated) of the Company for the quarter and half year ended September 30 2022. With reference to the captioned subject, we wish to inform you that: 1. The Meeting of the Board of Directors commenced at 12:30 pm (IST) and concluded at 06:35 pm (IST). 2. The unaudited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30, 2022 together with the Limited Review Report has been reviewed by the Audit Committee and considered and approved by the Board of Directors, has been enclosed herewith as Annexure-1. With reference to the captioned subject, we wish to inform you that: 1. The Meeting of the Board of Directors commenced at 12:30 pm (IST) and concluded at 06:35 pm (IST). 2. The unaudited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30, 2022 together with the Limited Review Report has been reviewed by the Audit Committee and considered and approved by the Board of Directors, has been enclosed herewith as Annexure-1. 3. Publication of the results in the Newspaper is being done as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. With reference to the captioned subject, we wish to inform you that, upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company at its meeting held today, November 10, 2022 has considered and approved the appointment of Mr. Emmanuel David Gootam (DIN: 09771151) as an Additional Director (Non Executive Independent Director) with effect from November 10, 2022, for a period of three years subject to approval of the shareholders. In this regard, as per Circular Number CIR/CFD/CMD/4/2015 dated September 09, 2015 pertaining to continuous disclosure requirements for Listed Entities under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Annexure I for your records. The composition of the Board of Directors after his appointment with effect from November 10, 2022, is enclosed as Annexure II for your records. In furtherance of the intimation made by the Company on March 28, 2022 and June 11, 2022, we wish to inform you that the board of directors ('Board') of the Company, at its meeting held on November 10, 2022, considered the updates since the last meeting on the potential restructuring options for the Company and unlocking value for the Company and its stakeholders. The Board was updated about the progress on the restructuring process. The investment bankers informed that they are in receipt of interest and indicative terms from various potential investors and are in the process of evaluating the same. Upon submission of the evaluation by investment bankers, the Board shall review the options for segregation of the Company's business in the Gulf Co operation Council region from its business in India. Appropriate announcements and public disclosures in accordance with the Listing Regulations and other applicable laws will be made as and when required, in this regard. (As per BSE Announcement Dated on 10/11/2022)

1 2

LOGIN HERE

Aster DM Healthcare Ltd

Board Meeting